HEFT Repository

Empagliflozin for the treatment of type 2 diabetes.

Jahagirdar, Vidhya and Barnett, Anthony H (2014) Empagliflozin for the treatment of type 2 diabetes. Expert opinion on pharmacotherapy, 15 (16). pp. 2429-41. ISSN 1744-7666. This article is accessible to all HEFT staff and students via NHS Evidence www.evidence.nhs.uk by using their HEFT Athens login IDs

Full text not available from this repository.
Official URL: http://informahealthcare.com/doi/abs/10.1517/14656...

Abstract

INTRODUCTION

Despite the availability of numerous anti-diabetes drugs and treatment guidelines, many patients with type 2 diabetes mellitus (T2DM) do not reach recommended targets for glycemic control. There remains an unmet need for effective and well-tolerated anti-diabetes agents that can be used as monotherapy or in combination with other therapies to improve glycemic control in patients with T2DM. Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of treatment for T2DM that reduce hyperglycemia by reducing renal glucose reabsorption and thereby increasing urinary glucose excretion.

AREAS COVERED

This paper reviews the pharmacokinetic and pharmacodynamic properties of the SGLT2 inhibitor empagliflozin , the results of clinical trials investigating the efficacy of empagliflozin given as monotherapy or as add-on therapy on glycemic control, body weight, and blood pressure in patients with T2DM, and the safety and tolerability profile of empagliflozin.

EXPERT OPINION

Empagliflozin offers good glycemic efficacy, weight loss, blood pressure reduction, and a low risk of hypoglycemia. These attributes, coupled with the ability to be used in virtually any combination with other anti-diabetes agents and at any stage in the disease process, provide a welcome new agent to our armamentarium of drugs to help manage T2DM.

Item Type: Article
Additional Information: This article is accessible to all HEFT staff and students via NHS Evidence www.evidence.nhs.uk by using their HEFT Athens login IDs
Subjects: WK Endocrine system. Endocrinology
Divisions: Ambulatory Care > Diabetes
Related URLs:
Depositing User: Mrs Caroline Tranter
Date Deposited: 06 Jul 2015 11:30
Last Modified: 06 Jul 2015 11:30
URI: http://www.repository.heartofengland.nhs.uk/id/eprint/1008

Actions (login required)

View Item View Item